Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

被引：15

作者：

Reichegger, Hermann ^{[1
]}

Jochum, Wolfram ^{[2
]}

Forbs, Diana ^{[2
]}

Hader, Claudia ^{[3
]}

Fruh, Martin ^{[1
]}

机构：

[1] Kantonsspital St Gallen, Dept Med Oncol & Hematol, Rorschacherstr 95, CH-9007 St Gallen, Switzerland

[2] Kantonsspital St Gallen, Inst Pathol, St Gallen, Switzerland

[3] Kantonsspital St Gallen, Dept Radiol & Nucl Med, St Gallen, Switzerland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 7-8期

关键词：

AZD9291; Osimertinib; Intracranial; Lung cancer; Response; EGFR mutation; T790M; EGFR-TKI; ACQUIRED-RESISTANCE; CANCER; AZD9291; METASTASES; INHIBITORS; MUTATION;

D O I：

10.1159/000446759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Osimertinib (AZD9291, Tagrisso) is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Case Report: Our report demonstrates that osimertinib is able to inhibit the growth of a radiotherapy- and surgery-refractory EGFR T790M-positive brain metastasis in a patient with lung adenocarcinoma. Conclusion: These data show that re-biopsy in EGFR-mutated non-small cell lung cancer patients with acquired TKI resistance should be performed. (C) 2016 S. Karger GmbH, Freiburg

引用

页码：461 / 463

页数：3

共 12 条

[1]

Ballard P, 2015, J THORAC ONCOL, V10, pS300

[2] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

[3] Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor [J].

Finlay, M. Raymond V. ;

Anderton, Mark ;

Ashton, Susan ;

Ballard, Peter ;

Bethel, Paul A. ;

Box, Matthew R. ;

Bradbury, Robert H. ;

Brown, Simon J. ;

Butterworth, Sam ;

Campbell, Andrew ;

Chorley, Christopher ;

Colclough, Nicola ;

Cross, Darren A. E. ;

Currie, Gordon S. ;

Grist, Matthew ;

Hassall, Lorraine ;

Hill, George B. ;

James, Daniel ;

James, Michael ;

Kemmitt, Paul ;

Klinowska, Teresa ;

Lamont, Gillian ;

Lamont, Scott G. ;

Martin, Nathaniel ;

McFarland, Heather L. ;

Mellor, Martine J. ;

Orme, Jonathon P. ;

Perkins, David ;

Perkins, Paula ;

Richmond, Graham ;

Smith, Peter ;

Ward, Richard A. ;

Waring, Michael J. ;

Whittaker, David ;

Wells, Stuart ;

Wrigley, Gail L. .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (20) :8249-8267

[4] Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Kaji, Reiko ;

Masago, Katsuhiro ;

Fujita, Shiro ;

Imai, Yukihiro ;

Nishiyama, Akihiro ;

Ishida, Tadashi ;

Nishimura, Yoshihiro ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) :1553-1559

[5]

Hata A, 2015, ANTICANCER RES, V35, P1025

[6] AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer [J].

Jaenne, Pasi A. ;

Yang, James Chih-Hsin ;

Kim, Dong-Wan ;

Planchard, David ;

Ohe, Yuichiro ;

Ramalingam, Suresh S. ;

Ahn, Myung-Ju ;

Kim, Sang-We ;

Su, Wu-Chou ;

Horn, Leora ;

Haggstrom, Daniel ;

Felip, Enriqueta ;

Kim, Joo-Hang ;

Frewer, Paul ;

Cantarini, Mireille ;

Brown, Kathryn H. ;

Dickinson, Paul A. ;

Ghiorghiu, Serban ;

Ranson, Malcolm .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18) :1689-1699

[7] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients [J].

Kuiper, J. L. ;

Heideman, D. A. M. ;

Thunnissen, E. ;

Paul, M. A. ;

van Wijk, A. W. ;

Postmus, P. E. ;

Smit, E. F. .

LUNG CANCER, 2014, 85 (01) :19-24

[8] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease [J].

Ohashi, Kadoaki ;

Maruvka, Yosef E. ;

Michor, Franziska ;

Pao, William .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1070-1080

[9] Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation [J].

Park, S. J. ;

Kim, H. T. ;

Lee, D. H. ;

Kim, K. P. ;

Kim, S. -W. ;

Suh, C. ;

Lee, J. S. .

LUNG CANCER, 2012, 77 (03) :556-560

[10] Epidermal Growth Factor Receptor-Mutant Lung Cancer New Drugs, New Resistance Mechanisms, and Future Treatment Options [J].

Piotrowska, Zofia ;

Sequist, Lecia V. .

CANCER JOURNAL, 2015, 21 (05) :371-377

← 1 2 →